{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:54:20Z","timestamp":1787496860362,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Health Syst."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Effective and interpretable molecular subtyping is critical for cancer risk stratification and treatment, yet existing methods face key limitations. Traditional models cannot jointly model multiple clinical endpoints, limiting prognostic utility, while machine learning (ML) approaches often lack transparency. We developed MuTATE, an automated, interpretable decision-tree framework powered by ML that improves subtyping accuracy and enables multi-endpoint risk stratification. MuTATE was evaluated using 18,400 simulations and 682 patient biopsies from three TCGA cancers: lower-grade glioma (LGG), endometrial carcinoma (EC), and gastric adenocarcinoma (GA). Compared to established clinical models, MuTATE improved accuracy, interpretability, and biomarker discovery, and reclassified risk groups. In LGG, MuTATE reassigned 13% of \u201clow-risk\u201d IDH-1p19q cases into higher-risk subtypes, and 19% of \u201chigh-risk\u201d IDH wild-type cases were reassigned to higher-risk categories. In GA, MuTATE refined the \u201cintermediate-risk\u201d genomically stable group into a higher-risk ARID1A wild-type subtype. In EC, 72% of \u201cintermediate-risk\u201d MSI\/MLH1 cases were reassigned to the highest-risk category. These findings demonstrate MuTATE\u2019s potential to reduce diagnostic bias, improve risk stratification, and support scalable integration of multi-endpoint ML into precision oncology workflows.<\/jats:p>","DOI":"10.1038\/s44401-025-00025-4","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:34:04Z","timestamp":1751528044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MuTATE: an interpretable multi-endpoint machine learning framework for automated molecular subtyping in cancer"],"prefix":"10.1038","volume":"2","author":[{"given":"Sarah G.","family":"Ayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Daniela","family":"Robles-Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Q.","family":"Fuentes-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Garza-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mart\u00ednez-Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Gerardo","family":"Tamez-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario R.","family":"Garcia-Pompermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. & Wisnivesky, J. The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol. 20, 624\u2013639 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"A Thrift","year":"2021","unstructured":"Thrift, A. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat. Rev. Gastroenterol. Hepatol. 18, 432\u2013443 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"L van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat. Rev. Clin. Oncol. 20, 287\u2013304 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"D Brat","year":"2015","unstructured":"Brat, D. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481\u20132498 (2015).","journal-title":"N. Engl. J. Med."},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"DA Levine","year":"2013","unstructured":"Levine, D. A. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67\u201373 (2013).","journal-title":"Nature"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","volume":"594","author":"MY Lu","year":"2021","unstructured":"Lu, M. Y. et al. AI-based pathology predicts origins for cancers of unknown primary. Nature 594, 106\u2013110 (2021).","journal-title":"Nature"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","volume":"158","author":"KA Hoadley","year":"2014","unstructured":"Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929\u2013944 (2014).","journal-title":"Cell"},{"key":"25_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06921-8","volume":"9","author":"D Ramazzotti","year":"2018","unstructured":"Ramazzotti, D. et al. Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival. Nat. Commun. 9, 4453 (2018).","journal-title":"Nat. Commun."},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1093\/bioinformatics\/btp543","volume":"25","author":"R Shen","year":"2009","unstructured":"Shen, R., Olshen, A. B. & Ladanyi, M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 25, 2906\u20132912 (2009).","journal-title":"Bioinformatics"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nmeth.2810","volume":"11","author":"B Wang","year":"2014","unstructured":"Wang, B. et al. Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods 11, 333\u2013337 (2014).","journal-title":"Nat. Methods"},{"key":"25_CR13","unstructured":"Louis, D. et al. WHO Classification of Tumours of the Central Nervous System. WHO Classification of Tumours (International Agency for Research on Cancer, 2016)."},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller, M. et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315\u2013e329 (2017).","journal-title":"Lancet Oncol."},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344\u20131355 (2016).","journal-title":"N. Engl. J. Med."},{"key":"25_CR16","first-page":"242","volume":"19","author":"M Wahl","year":"2017","unstructured":"Wahl, M. et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 19, 242\u2013251 (2017).","journal-title":"Neuro Oncol."},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11060-019-03277-x","volume":"145","author":"R Rud\u00e0","year":"2019","unstructured":"Rud\u00e0, R. et al. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. J. Neuro-Oncol. 145, 115\u2013123 (2019).","journal-title":"J. Neuro-Oncol."},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","volume":"28","author":"AS Jakola","year":"2017","unstructured":"Jakola, A. S. et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann. Oncol. 28, 1942\u20131948 (2017).","journal-title":"Ann. Oncol."},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell, E. H. et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J. Clin. Oncol. 38, 3407\u20133417 (2020).","journal-title":"J. Clin. Oncol."},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","volume":"390","author":"MJ van den Bent","year":"2017","unstructured":"van den Bent, M. J. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390, 1645\u20131653 (2017).","journal-title":"Lancet"},{"key":"25_CR21","doi-asserted-by":"publisher","first-page":"iii3","DOI":"10.1093\/neuonc\/noz126.006","volume":"21","author":"MJ van den Bent","year":"2019","unstructured":"van den Bent, M. J. et al. PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q codeletion. Neuro Oncol. 21, iii3 (2019).","journal-title":"Neuro Oncol."},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gim.2021.09.006","volume":"24","author":"SG Ayton","year":"2022","unstructured":"Ayton, S. G. et al. Multiomics subtyping for clinically prognostic cancer subtypes and personalized therapy: A systematic review and meta-analysis. Genet. Med. 24, 15\u201325 (2022).","journal-title":"Genet. Med."},{"key":"25_CR23","doi-asserted-by":"crossref","unstructured":"Quinlan, J. R. Combining instance-based and model-based learning. In: Proc. 9th International Workshop on Machine Learning, 236\u2013243 (Morgan Kaufmann Publishers Inc., 1992).","DOI":"10.1016\/B978-1-55860-307-3.50037-X"},{"key":"25_CR24","first-page":"851","volume":"27","author":"RE Schapire","year":"1999","unstructured":"Schapire, R. E. et al. Boosting the margin: a new explanation for the effectiveness of voting methods. Ann. Stat. 27, 851\u2013876 (1999).","journal-title":"Ann. Stat."},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00058655","volume":"24","author":"L Breiman","year":"1996","unstructured":"Breiman, L. Bagging predictors. Mach. Learn. 24, 123\u2013140 (1996).","journal-title":"Mach. Learn."},{"key":"25_CR26","doi-asserted-by":"crossref","unstructured":"Friedman, J. H. Greedy function approximation: a gradient boosting machine. Ann. Stat. 29,1189\u20131232 (2001).","DOI":"10.1214\/aos\/1013203451"},{"key":"25_CR27","unstructured":"Ho, T. K. Random decision forests. In: Proc. 3rd International Conference on Document Analysis and Recognition. Vol. 1 (IEEE, 1995)."},{"key":"25_CR28","unstructured":"Wang, W. & Sebag, M. Multi-objective Monte-Carlo tree search. In: C. H. H. Steven and B. Wray, Editors Proc. Asian Conference on Machine Learning. 507\u2013522 (PMLR, 2012)."},{"key":"25_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ins.2019.08.034","volume":"507","author":"JY Jeong","year":"2020","unstructured":"Jeong, J. Y., Kang, J. S. & Jun, C. H. Regularization-based model tree for multi-output regression. Inf. Sci. 507, 240\u2013255 (2020).","journal-title":"Inf. Sci."},{"key":"25_CR30","first-page":"2409","volume":"31","author":"D Xu","year":"2019","unstructured":"Xu, D. et al. Survey on multi-output learning. IEEE Trans. Neural Netw. Learn. Syst. 31, 2409\u20132429 (2019).","journal-title":"IEEE Trans. Neural Netw. Learn. Syst."},{"key":"25_CR31","doi-asserted-by":"crossref","unstructured":"Yoon, C. H., Torrance, R. & Scheinerman, N. Machine learning in medicine: should the pursuit of enhanced interpretability be abandoned? J. Med. Ethics 48, 581\u2013585 (2021).","DOI":"10.1136\/medethics-2020-107102"},{"key":"25_CR32","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/ijms22094394","volume":"22","author":"AJ Banegas-Luna","year":"2021","unstructured":"Banegas-Luna, A. J. et al. Towards the interpretability of machine learning predictions for medical applications targeting personalised therapies: a cancer case survey. Int. J. Mol. Sci. 22, 4394 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"25_CR33","unstructured":"Breiman, L. et al. Classification and Regression Trees (Chapman & Hall\/CRC, 1984)."},{"key":"25_CR34","first-page":"626","volume":"33","author":"S Lin","year":"2021","unstructured":"Lin, S., Azarnoush, B. & Runger, G. C. MTBR: multi-target boosting for regression. IEEE Trans. Knowl. Data Eng. 33, 626\u2013636 (2021).","journal-title":"IEEE Trans. Knowl. Data Eng."},{"key":"25_CR35","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s10994-020-05894-4","volume":"109","author":"D Kocev","year":"2020","unstructured":"Kocev, D., Ceci, M. & Stepi\u0161nik, T. Ensembles of extremely randomized predictive clustering trees for predicting structured outputs. Mach. Learn 109, 2213\u20132241 (2020).","journal-title":"Mach. Learn"},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10994-019-05829-8","volume":"109","author":"M Petkovi\u0107","year":"2020","unstructured":"Petkovi\u0107, M., Kocev, D. & D\u017eeroski, S. Feature ranking for multi-target regression. Mach. Learn. 109, 1179\u20131204 (2020).","journal-title":"Mach. Learn."},{"key":"25_CR37","doi-asserted-by":"crossref","unstructured":"Adlung, L. et al. Machine learning in clinical decision making. Medicines 2, 642\u2013665 (2021).","DOI":"10.1016\/j.medj.2021.04.006"},{"key":"25_CR38","doi-asserted-by":"crossref","unstructured":"Yung, A. et al. Computer-based decision tools for shared therapeutic decision-making in oncology: systematic review. JMIR Cancer 7, e31616 (2021).","DOI":"10.2196\/31616"},{"key":"25_CR39","doi-asserted-by":"crossref","unstructured":"Engelhardt, D. & Michor, F. A quantitative paradigm for decision-making in precision oncology. Trends Cancer 7, 293\u2013300 (2021).","DOI":"10.1016\/j.trecan.2021.01.006"},{"key":"25_CR40","doi-asserted-by":"crossref","unstructured":"Couckuyt, A. et al. Challenges in translational machine learning. Hum. Genet. 141,1451\u20131466 (2022).","DOI":"10.1007\/s00439-022-02439-8"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7326\/M19-2548","volume":"172","author":"F Wang","year":"2020","unstructured":"Wang, F., Kaushal, R. & Khullar, D. Should health care demand interpretable artificial intelligence or accept \u201cBlack Box\u201d medicine? Ann. Intern. Med. 172, 59\u201360 (2020).","journal-title":"Ann. Intern. Med."},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.gim.2021.10.015","volume":"24","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank. Genet. Med. 24, 601\u2013609 (2022).","journal-title":"Genet. Med."},{"key":"25_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11112-0","volume":"10","author":"L Duncan","year":"2019","unstructured":"Duncan, L. et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat. Commun. 10, 3328 (2019).","journal-title":"Nat. Commun."},{"key":"25_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.gim.2021.11.016","volume":"24","author":"T Pal","year":"2022","unstructured":"Pal, T. Diversity in cancer genomics research is a matter of equity and scientific discovery. Genet. Med. 24, 549\u2013551 (2022).","journal-title":"Genet. Med."},{"key":"25_CR45","doi-asserted-by":"publisher","first-page":"btad507","DOI":"10.1093\/bioinformatics\/btad507","volume":"39","author":"S Ayton","year":"2023","unstructured":"Ayton, S. & Trevi\u00f1o, V. MuTATE-an R package for comprehensive multi-objective molecular modeling. Bioinformatics 39, btad507 (2023).","journal-title":"Bioinformatics"},{"key":"25_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03154-8","volume":"23","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. The effects of ARID1A mutation in gastric cancer and its significance for treatment. Cancer Cell Int. 23, 296 (2023).","journal-title":"Cancer Cell Int."},{"key":"25_CR47","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data. Brief Bioinform. 26, bbae648 (2024).","DOI":"10.1093\/bib\/bbae648"},{"key":"25_CR48","doi-asserted-by":"publisher","first-page":"995180","DOI":"10.3389\/fimmu.2022.995180","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. TMBcat: a multi-endpoint. Front. Immunol. 13, 995180 (2022).","journal-title":"Front. Immunol."},{"key":"25_CR49","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","volume":"39","author":"AZ Torres","year":"2022","unstructured":"Torres, A. Z. et al. Analysis of a real-world progression variable and related endpoints for patients with five different cancer types. Adv. Ther. 39, 2831\u20132849 (2022).","journal-title":"Adv. Ther."},{"key":"25_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00262-024-03829-9","volume":"73","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients. Cancer Immunol. Immunother. 73, 241 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"25_CR51","doi-asserted-by":"crossref","unstructured":"Shi, Z. et al. Application of random survival forest to establish a nomogram combining clinlabomics-score and clinical data for predicting brain metastasis in primary lung cancer. Clin. Transl. Oncol. 27, 1472\u20131483 (2024).","DOI":"10.1007\/s12094-024-03688-x"},{"key":"25_CR52","doi-asserted-by":"publisher","first-page":"e0000606","DOI":"10.1371\/journal.pdig.0000606","volume":"3","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Aspiring to clinical significance: insights from developing and evaluating a machine learning model to predict emergency department return visit admissions. PLOS Digit Health 3, e0000606 (2024).","journal-title":"PLOS Digit Health"},{"key":"25_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00754-z","volume":"8","author":"Y Xia","year":"2024","unstructured":"Xia, Y. et al. Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer. NPJ Precis. Oncol. 8, 263 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"25_CR54","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1109\/TKDE.2022.3207511","volume":"35","author":"W Huang","year":"2023","unstructured":"Huang, W. et al. HmcNet: a general approach for hierarchical multi-label classification. IEEE Trans. Knowl. Data Eng. 35, 8713\u20138728 (2023).","journal-title":"IEEE Trans. Knowl. Data Eng."},{"key":"25_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/nox132","volume":"20","author":"K Aoki","year":"2018","unstructured":"Aoki, K. et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 20, 66\u201377 (2018).","journal-title":"Neuro Oncol."},{"key":"25_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13046-019-1319-4","volume":"38","author":"L Yi","year":"2019","unstructured":"Yi, L. et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12\/CXCR4. J. Exp. Clin. Cancer Res. 38, 339 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"25_CR57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","volume":"126","author":"B Wiestler","year":"2013","unstructured":"Wiestler, B. et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol,126, 443\u2013451 (2013).","journal-title":"Acta Neuropathol,"},{"key":"25_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo, F. et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. 25, 176\u2013187 (2019).","journal-title":"Nat. Med."},{"key":"25_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt, A. et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol. 136, 273\u2013291 (2018).","journal-title":"Acta Neuropathol."},{"key":"25_CR60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41575-022-00591-0","volume":"19","author":"Y Zavros","year":"2022","unstructured":"Zavros, Y. & Merchant, J. L. The immune microenvironment in gastric adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 19, 451\u2013467 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"25_CR61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-19-0811","volume":"10","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 10, 288\u2013305 (2020).","journal-title":"Cancer Discov."},{"key":"25_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"Kakiuchi, M. et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet. 46, 583\u2013587 (2014).","journal-title":"Nat. Genet."},{"key":"25_CR63","doi-asserted-by":"crossref","unstructured":"Veas, J. et al. PD-2 Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. Ann. Oncol. 34, S1 (2023).","DOI":"10.1016\/j.annonc.2023.04.029"},{"key":"25_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ccell.2017.11.018","volume":"33","author":"KK Huang","year":"2018","unstructured":"Huang, K. K. et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell 33, 137\u2013150.e5 (2018).","journal-title":"Cancer Cell"},{"key":"25_CR65","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41588-020-0665-7","volume":"52","author":"A Okabe","year":"2020","unstructured":"Okabe, A. et al. Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma. Nat. Genet 52, 919\u2013930 (2020).","journal-title":"Nat. Genet"},{"key":"25_CR66","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","volume":"33","author":"A Pasanen","year":"2020","unstructured":"Pasanen, A., Loukovaara, M. & B\u00fctzow, R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod. Pathol. 33, 1443\u20131452 (2020).","journal-title":"Mod. Pathol."},{"key":"25_CR67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.5372","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo, A. et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J. Pathol. 250, 323\u2013335 (2020).","journal-title":"J. Pathol."},{"key":"25_CR68","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/cancers13112623","volume":"13","author":"A Santoro","year":"2021","unstructured":"Santoro, A. et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO\/ESTRO\/ESP guidelines. Cancers13, 2623 (2021).","journal-title":"Cancers"},{"key":"25_CR69","doi-asserted-by":"crossref","unstructured":"Rankin, D. et al. Reliability of supervised machine learning using synthetic data in health care: model to preserve privacy for data sharing. JMIR Med. Inform. 8, e18910 (2020).","DOI":"10.2196\/18910"},{"key":"25_CR70","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109\u20131112 (2016).","journal-title":"N. Engl. J. Med."},{"key":"25_CR71","unstructured":"Therneau, T., Atkinson, B. & Ripley, B. Recursive partitioning and regression trees. CRAN: https:\/\/CRAN.R-project.org\/package=rpart (2022)."}],"container-title":["npj Health Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00025-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00025-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00025-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:03:25Z","timestamp":1751529805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00025-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1038\/s44401-025-00025-4","relation":{},"ISSN":["3005-1959"],"issn-type":[{"value":"3005-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}